CoronaStem 1 Trial - Personalized Stem Cells Files for Expedited FDA Approval to Treat COVID-19 Patients
Personalized Stem Cells, Inc. filed an FDA request for accelerated review of its COVID-19 stem cell treatment IND application. POWAY, CALIFORNIA, USA, April 21, 2020 /EINPresswire.com/ -- Personalized Stem Cells, Inc. (PSC) and its parent company, VetStem Biopharma, have filed an expedited review request for an Investigational New Drug (IND) application with the FDA for the treatment of COVID-19 patients with stem cells. The first trial is named “CoronaStem 1” and will provide treatment for twenty …